Revelation Biosciences (NASDAQ:REVB) Stock Scheduled to Reverse Split on Tuesday, October 20th

Revelation Biosciences, Inc. (NASDAQ:REVB)’s stock is going to reverse split on the morning of Tuesday, October 20th. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 19th.

Revelation Biosciences Trading Down 36.4%

REVB traded down $0.28 during midday trading on Friday, reaching $0.48. The company’s stock had a trading volume of 632,488 shares, compared to its average volume of 40,664. The firm has a market capitalization of $1.93 million, a price-to-earnings ratio of -0.04 and a beta of -0.07. Revelation Biosciences has a 1 year low of $0.47 and a 1 year high of $5.80. The stock’s 50-day moving average is $0.94 and its 200-day moving average is $1.03.

Revelation Biosciences (NASDAQ:REVB) last announced its earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.01. As a group, equities research analysts forecast that Revelation Biosciences will post -5.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Revelation Biosciences has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that activate and regulate the body’s innate immune system. Its research is aimed primarily at addressing infectious diseases and inflammatory conditions, particularly those affecting the respiratory system.

The company’s pipeline includes intranasal product candidates designed to stimulate localized immune responses in the nose and airways. Its lead candidate, REVTx-99, has been developed as an investigational therapy for respiratory conditions, including the prevention or reduction of complications associated with severe respiratory infections.